Coherus Oncology (CHRS) Total Debt (2014 - 2026)

Coherus Oncology's Total Debt history runs 13 years deep, the most recent figure standing at $37.1 million for Q1 2026.

• In Q1 2026, Total Debt fell 41.04% year-over-year to $37.1 million; the TTM figure through Mar 2026 stood at $37.1 million (down 41.04% YoY), while the FY2025 annual figure was $37.1 million, down 26.37% from the prior year.
• Total Debt came in at $37.1 million for Q1 2026 at Coherus Oncology, roughly flat from $37.1 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $250.3 million in Q3 2023 to a low of $36.9 million in Q2 2025.
• A 5-year average of $135.3 million and a median of $72.5 million in 2024 frame the typical range for Total Debt.
• Across the five-year window, Total Debt soared 225.99% in 2022 and slumped 81.69% in 2024, its largest moves.
• Coherus Oncology's Total Debt stood at $245.5 million in 2022, then increased by 1.75% to $249.8 million in 2023, then slumped by 79.86% to $50.3 million in 2024, then dropped by 26.37% to $37.1 million in 2025, then rose by 0.26% to $37.1 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $37.1 million, $37.1 million, and $37.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison